Statin-Induced Decrease in ATP-Binding Cassette Transporter A1 Expression via microRNA33 Induction may Counteract Cholesterol Efflux to High-Density Lipoprotein

Cardiovascular Drugs and Therapy

Volumn 29, Issue 1, 2015, Pages 7-14

  Niesor, Eric J ^a   Schwartz, Gregory G ^b   Perez, Anne ^a   Stauffer, Andrea ^a   Durrwell, Alexandre ^a   Bucklar Suchankova, Gabriela ^a   Benghozi, Renée ^a   Abt, Markus ^a   Kallend, David ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

ABCA1; Cholesterol efflux; HDL; microRNA33; Statin

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ACETYL LOW DENSITY LIPOPROTEIN; ATORVASTATIN; CHOLESTEROL; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MICRORNA; MICRORNA 33; PITAVASTATIN; PRAVASTATIN; PRE BETA HIGH DENSITY LIPOPROTEIN; RETINOID X RECEPTOR; ROSUVASTATIN; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; UNCLASSIFIED DRUG; ABC TRANSPORTER; ABCG1 PROTEIN, HUMAN; MIRN133 MICRORNA, HUMAN; MIRN33 MICRORNA, MOUSE;

ANIMAL CELL; ARTICLE; CHOLESTEROL EFFLUX; CHOLESTEROL METABOLISM; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EXPOSURE; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; CELL LINE; GENETICS; METABOLISM;

ANIMALS; ATP BINDING CASSETTE TRANSPORTER 1; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; MICE; MICRORNAS; RECEPTORS, LDL; RNA, MESSENGER; SIMVASTATIN;

EID: 84925489354     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-015-6570-0     Document Type: Article

References (32)

1. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15.
2. Oram JF, Lawn RM, Garvin MR, Wade DP. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem. 2000;275:34508–11.
3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.
4. Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010;376:333–9.
5. Niesor EJ, Magg C, Ogawa N, Okamoto H, von der Mark E, Matile H, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010;51:3443–54.
6. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–99.
7. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67.
8. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013, 34:1279–1291.
9. Attie AD, Kastelein JP, Hayden MR. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res. 2001;42:1717–26.
10. Bochem AE, van Wijk DF, Holleboom AG, Duivenvoorden R, Motazacker MM, Dallinga-Thie GM, et al. ABCA1 mutation carriers with low high-density lipoprotein cholesterol are characterized by a larger atherosclerotic burden. Eur Heart J. 2013;34:286–91.
11. Rosenson RS, Brewer Jr HB, Davidson WS, Fayad ZA, Fuster V, Goldstein J, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 2012;125:1905–19.
12. Altilia S, Pisciotta L, Garuti R, Tarugi P, Cantafora A, Calabresi L, et al. Abnormal splicing of ABCA1 pre-mRNA in Tangier disease due to a IVS2 + 5G>C mutation in ABCA1 gene. J Lipid Res. 2003;44:254–64.
13. Wellington CL, Yang YZ, Zhou S, Clee SM, Tan B, Hirano K, et al. Truncation mutations in ABCA1 suppress normal upregulation of full-length ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol. J Lipid Res. 2002;43:1939–49.
14. Goldstein JL, Bose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell. 2006;124:35–46.
15. Horie T, Ono K, Horiguchi M, et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci U S A. 2010;107:17321–6.
16. Wong J, Quinn CM, Brown AJ. SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR. Biochem J. 2006;400:485–91.
17. Venkateswaran A, Laffitte BA, Joseph SB, et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci U S A. 2000;97:12097–102.
18. Sato R. Sterol metabolism and SREBP activation. Arch Biochem Biophys. 2010;501:177–81.
19. Marquart TJ, Allen RM, Ory DS. Baldan A: miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci U S A. 2010;107:12228–32.
20. Najafi-Shoushtari SH, Kristo F, Li Y, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science. 2010;328:1566–9.
21. Rayner KJ, Suarez Y, Davalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science. 2010;328:1570–3.
22. Maugeais C, Perez A, von der Mark E, Magg C, Pflieger P, Niesor EJ. Evidence for a role of CETP in HDL remodeling and cholesterol efflux: role of cysteine 13 of CETP. Biochim Biophys Acta. 1831;1831:1644–50.
23. Genvigir FDV, Rodrigues AC, Cerda A, et al. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells. Pharmacogenomics. 2010;11:1235–46.
24. Wang W, Song W, Wang Y, Chen L, Yan X. HMG-CoA reductase inhibitors, simvastatin and atorvastatin, downregulate ABCG1-mediated cholesterol efflux in human macrophages. J Cardiovasc Pharmacol. 2013;62:90–8.
25. Yvan-Charvet L, Welch C, Pagler TA, Ranalletta M, Lamkanfi M, Han S, et al. Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation. 2008;118:1837–47.
26. Horie T, Nishino T, Baba O, Kuwabara Y, Nakao T, Nishiga M, et al. MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo. Sci Rep. 2014;4:5312.
27. Niesor EJ, Chaput E, Mary JL, Staempfli A, Topp A, Stauffer A, et al. Effect of compounds affecting ABCA1 expression and CETP activity on the HDL pathway involved in intestinal absorption of lutein and zeaxanthin. Lipids. 2014;49:1233–43.
28. Brunham LR, Kruit JK, Pape TD, Timmins JM, Reuwer AQ, Vasanji Z, et al. Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment. Nat Med. 2007;13:340–7.
29. Bellia A, Rizza S, Lombardo MF, Donadel G, Fabiano R, Andreadi K, et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis. 2012;223:197–203.
30. Wijesekara N, Zhang LH, Kang MH, Abraham T, Bhattacharjee A, Warnock GL, et al. Hayden MR: miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes. 2012;61:653–8.
31. Cerda A, Hirata MH, Hirata RDC. Molecular mechanisms underlying statin effects on genes involved in the reverse cholesterol transport. Drug Metabol Drug Interact. 2012;27:101–11.
32. Mao M, Lei H, Liu Q, Chen Y, Zhao L, Li Q, et al. Effects of miR-33a-5P on ABCA1/G1-mediated cholesterol efflux under inflammatory stress in THP-1 macrophages. PLoS One. 2014;9:e109722.